Evidence map›Paper›PMID 42420634›Full record

ReviewEJNMMI reports2026

FAPI: a solution to all, what about NENs?

Ozgul Ekmekcioglu, Filiz Celik, Simon Hughes, Meltem Ocak, Fred Verzijlbergen, Stefano Fanti, Christophe M Deroose

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ozgul EkmekciogluNuclear Medicine Department, Yeditepe University Medical Faculty, Kosuyolu, Istanbul, Türkiye. ozgulek@gmail.com.ORCID http://orcid.org/0000-0002-3313-8087
Filiz CelikDeventer Hospital, Center for Radiology and Nuclear Medicine, Department of Nuclear Medicine, Deventer, The Netherlands.
Simon HughesQueen Elizabeth Hospital, Radiology and Nuclear Medicine Department, University of Birmignham, Birmingham, UK.
Meltem OcakMolecular Imaging and Theranostic Center, University of Missouri, Columbia, MO, USA.
Fred VerzijlbergenRadiology and Nuclear Medicine Department, University of Radboud, Nijmegen, Netherlands.
Stefano FantiIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Christophe M DerooseNuclear Medicine, University Hospitals Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein (FAP)-targeted PET imaging is an emerging technique that images the tumor stroma by targeting cancer-associated fibroblasts, offering high tumor-to-background contrast and improved lesion detection in tumors with low [¹⁸F]FDG avidity. Given the central role of CAFs in tumor progression and therapy response, FAPI PET has gained interest in neuroendocrine neoplasms (NENs), where stromal imaging may provide complementary information to conventional modalities. This review evaluates the biological rationale, current evidence, and potential clinical role of FAPI PET in the imaging and management of NENs.

Indexed as

FAPIFibroblast activation proteinNeuroendocrine tumorsPET/CT

Identifiers

PMID42420634
PMCPMC13346405

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.